We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Exlusive interview with Petrovax Pharm Company, responsible for launching a phase III trial for the COVID-19 vaccine developed by CanSino Biologics Inc. This issue features Nikolay Dodonov, the Head of Medical Department at Petrovax Pharm, sharing first-hand insights on the clinical development process for a COVID-19 vaccine trial.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
